История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $3.4B | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788M | $451M | $162M | $15M | $20M | $0M | $3M | $53M | $77M | $34M | $3M | $4M | $1M | $39M |
| Валовая прибыль | $3.3B | $2.8B | $2.3B | $1.8B | $1.5B | $1.1B | $1.0B | $781M | $446M | $160M | $15M | $20M | ($14M) | ($11M) | $42M | $77M | $34M | $3M | $4M | $1M | $39M |
| Валовая маржа % | 98.0% | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% | 100.0% | — | -372.8% | 78.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Операционная прибыль (EBIT) | $789M | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | ($131M) | ($147M) | ($94M) | ($64M) | ($50M) | $1M | $34M | ($14M) | ($54M) | ($87M) | ($212M) | ($113M) |
| Операционная маржа % | 23.4% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | -476.5% | — | -1701.9% | 2.7% | 43.8% | -41.0% | -1817.5% | -2196.2% | -17340.0% | -288.8% |
| Чистая прибыль | $706M | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | ($143M) | ($141M) | ($89M) | ($61M) | ($46M) | $5M | $38M | ($8M) | ($51M) | ($89M) | ($207M) | ($107M) |
| Чистая маржа % | 20.9% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | -449.8% | — | -1579.0% | 9.5% | 48.5% | -23.8% | -1728.3% | -2229.3% | -16936.2% | -273.2% |
| EBITDA | — | $667M | $640M | $416M | $265M | $138M | $148M | $86M | $41M | ($121M) | ($140M) | ($88M) | ($64M) | ($49M) | $2M | $35M | ($12M) | ($48M) | ($74M) | ($203M) | ($103M) |
| Прибыль на акцию (EPS) | $6.84 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | $-0.69 | $0.08 | $0.67 | $-0.15 | $-1.30 | $-2.30 | $-5.45 | $-2.84 |
| Акции в обращении (M) | — | 102M | 104M | 101M | 99M | 98M | 98M | 96M | 95M | 88M | 87M | 84M | 75M | 67M | 67M | 56M | 53M | 39M | 38M | 38M | 38M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике NBIX. /companies/us/NBIX
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms